Entera Bio's EB613, an oral PTH(1-34) tablet for post-menopausal women with osteoporosis, shows promising comparative pharmacological data presented at ASBMR 2024.
Entera Bio and OPKO Health reported positive pharmacokinetic/pharmacodynamic (PK/PD) results for their oral oxyntomodulin (OXM) tablet candidate targeting obesity and metabolic disorders.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.